Biotechnology analysis: characterize and secure your biopharmaceuticals in the laboratory

In biopharmaceutical, the development of a biopharmaceutical requires rigorous analytical oversight to confirm the identity of the molecule, document its structure, monitor its stability, and detect critical impurities or contaminants. In a demanding biopharmaceutical environment, teams must produce reliable data for R&D, process optimization, batch comparability, and regulatory testing. An biotechnology analysis approach therefore makes it possible to secure biopharmaceuticals at every key stage, from initial characterization through to quality monitoring.

Identity confirmation of a biotherapeutic product relies on several levels of analytical interpretation. The primary sequence can be studied by peptide mapping and De Novo sequencing by HPLC-MS/MS. The intact molecular mass can be determined accurately by HPLC-HRMS or by SEC with triple detection. Disulfide bonds and free sulfhydryl groups can also be located to better understand the molecule’s architecture and verify its structural consistency.

The stability of a biopharmaceutical must be monitored through sensitive structural and physicochemical parameters. Analysis of secondary and tertiary structures by FTIR spectroscopy, circular dichroism, and UV/Visible profiles usefully complements the study of thermal stability by DSC. In parallel, targeted or exploratory methods make it possible to search for process impurities, degradation products, regulated traces, or particulate contaminants depending on the matrix under study.

Outsourcing the management of your analytical methods makes it possible to quickly mobilize expert resources, reduce internal workload, and speed up data generation timelines. The laboratory can handle all or part of the project: feasibility study, method development, optimization, analytical validation, and then transfer to the client site. This setup is particularly useful when internal teams lack time or need to secure a critical development stage.

FILAB supports biopharmaceutical players in the development, optimization, validation, and transfer of analytical methods adapted to biomolecules and biotherapeutic products. The laboratory works on structure confirmation, primary sequence analysis, intact mass measurement, disulfide bond analysis, characterization of secondary and tertiary structures, as well as thermal stability assessment. This approach provides actionable results to speed up decision-making and reduce analytical risks for your biopharmaceuticals.

To take characterization further, FILAB relies on a state-of-the-art instrument fleet including LC-UV, LC-MS/MS, LC-QTOF/MS, LC-RI, LC-CAD, LC-ELSD, GC-MS, ICP-MS, and ion chromatography. Depending on your needs, these tools are used for active substance assay, impurity testing, identification of unknown compounds, or stability monitoring. For certain volatile or residual compound issues, an approach using Hs Gc Ms Laboratory Analysis may be relevant.

In the context of batch comparability, the challenge is to objectify the differences between a compliant batch and a non-compliant batch, or between several productions resulting from a change in process, raw material, or supplier. FILAB can set up comparative studies, identify an impurity by LC-HRMS, and produce analytical data useful for interpreting discrepancies. Additional investigations on material or particles can also rely on Meb Analysis Laboratory or Met Analysis Laboratory depending on the nature of the need.

FILAB operates in a GMP environment and holds COFRAC accreditation according to ISO 17025 for publicly available scopes. The laboratory is independent, recognized under the Research Tax Credit scheme, and mobilizes human, technical, and documentary resources suited to industrial challenges. This combination strengthens the reliability of the data produced and the relevance of the solutions proposed. For projects with an innovation dimension, it may be useful to consult the Laboratoire Agree Cir page.

To initiate a study, the first step is to clarify the objective: confirm a structure, compare batches, develop a method, look for an impurity, or document stability. FILAB experts then define the most suitable analytical strategy based on the matrix, regulatory constraints, and the expected level of detail. Support may include method development, validation, and transfer. Depending on the material issue, complementary approaches such as Analyse Inclusion Laboratoire can enrich the investigation. Contact an expert, define your specifications, submit your samples, obtain actionable results, secure your analytical decisions.